Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

provet s. a. - Дигидрострептомицин (като сулфат Дигидрострептомицин) - инжекционен разтвор - 250 mg/ml - говеда, кози, кучета, овце, свине

Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

bioveta, a.s. - Линкомицин (под формата на хидрохлорид); неомицина сулфат - интрамамарен разтвор - 330 mg/10 ml; 100,000 iu/10 ml - крави

Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

laboratorios syva, s.a.u. - Бензилпенициллин прокаин; Дигидрострептомицин (под формата на сулфат) - инжекционна суспензия - 200 000 iu/ml; 250 mg/ml - говеда, кози, коне, овце, свине

Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

Завет АД - Тетрациклин хидрохлорид; сулфат неомицина, бацитрацина, преднизолона ацетат - интрамамарна маз - 200 000 iu; 100 000 iu; 2000 iu; 0.0100 g/10 g - крави

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

mylan ire healthcare limited - pretomanid - Туберкулоза, мултирезистентни - Антимикобактериални - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). Трябва да се вземат предвид официалните препоръки за правилното използване на антибактериални агенти.

Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

ДСМ ДЕНИТРАНС ООД - streptomycin sulfate - перорален прах - 1 g/g - прасета, телета

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - доксорубицин хидрохлорид - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - Антинеопластични средства - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).